G-CSF reduces febrile neutropenia and mortality risk

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1598, 2007-01, pp. : 14-14

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

G-CSF as prophylaxis of febrile neutropenia in SCLC

By Feinglass Joe   Adams Jared R   Djubegovic Benjamin   Bennett Charles L   Lyman Gary H  

Expert Opinion on Pharmacotherapy, Vol. 3, Iss. 9, 2002-09 ,pp. : 1273-1281

Informa Healthcare

Access to resources Recommend Favorite

New G-CSF agonists for neutropenia therapy

By Hoggatt Jonathan   Pelus Louis M  

Expert Opinion on Investigational Drugs, Vol. 23, Iss. 1, 2014-01 ,pp. : 21-35

Informa Healthcare

Access to resources Recommend Favorite

G-CSF linked to GVHD

By  

Reactions Weekly, Vol. 1, Iss. 1327, 2010-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Granulocyte colony-stimulating factor (G-CSF) appears to increase the risk of therapy-related myeloid leukaemia

By  

Inpharma, Vol. 1, Iss. 1394, 2003-01 ,pp. : 20-20

Adis International

Access to resources Recommend Favorite

Febrile neutropenia costly in the US

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 661, 2012-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite